Cargando…
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria
Neonatal sepsis causes up to an estimated 680,000 deaths annually worldwide, predominantly in low- and middle-income countries (LMICs). A significant and growing proportion of bacteria causing neonatal sepsis are resistant to multiple antibiotics, including the World Health Organization-recommended...
Autores principales: | Darlow, Christopher A., da Costa, Renata M. A., Ellis, Sally, Franceschi, François, Sharland, Mike, Piddock, Laura, Das, Shampa, Hope, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418595/ https://www.ncbi.nlm.nih.gov/pubmed/34435316 http://dx.doi.org/10.1007/s40272-021-00465-z |
Ejemplares similares
-
Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance
por: Darlow, Christopher A., et al.
Publicado: (2022) -
Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings
por: Darlow, Christopher A, et al.
Publicado: (2022) -
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2021) -
Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2022) -
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales—authors’ response
por: Darlow, Christopher A, et al.
Publicado: (2022)